FindTrial
Sign In

PAS-004 Tablets

DRUG2 trials

Sponsors

Pasithea Therapeutics Corp.

Conditions

Advanced Solid TumorsNF1 MutationNeurofibroma PlexiformNeurofibroma, PlexiformNeurofibromatosis Type 1 (NF1)Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)RAF MutationRAS Mutation

Phase 1

PAS-004 in Patients With Advanced Solid Tumors
RecruitingNCT06299839
Pasithea Therapeutics Corp.Advanced Solid Tumors, NF1 Mutation, RAF Mutation +1
Start: 2024-02-29End: 2027-02-28Target: 48Updated: 2025-12-03
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
RecruitingNCT06961565
Pasithea Therapeutics Corp.Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1) +2
Start: 2025-05-30End: 2027-12-31Target: 56Updated: 2025-12-04

Related Papers

Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors.
Journal of Clinical Oncology2025-05-28